EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Investigating preeclampsia risk factors and angiogenic profiles in low-screening area

Adriana Bokulić iD, Dražan Butorac iD, Ivka Djaković iD, Marijo Čukelj iD, Marija Grdić Rajković iD

Acta Pharmaceutica · 2025

DOI: 10.2478/acph-2025-0040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica, 2025. Verfasst von Adriana Bokulić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Sestre Milosrdnice University Hospital Center, Department of Clinical Chemistry, 10000 Zagreb Croatia. Hauptthemen laut MEDLINE: Pre-Eclampsia, Vascular Endothelial Growth Factor Receptor-1, Placenta Growth Factor, Angiogenesis. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preeclampsia (PE) is a complex pregnancy disorder that may cause adverse outcomes for mother and baby. Combining risk factors with clinical, laboratory, and ultrasonographic data can help identify women at risk. This study investigated the relationship between maternal risk factors, soluble fms-like tyro-sine kinase 1 (sFlt-1), placental growth factor (PlGF), their ratio, and pregnancy outcomes, involving 68 women with PE risk factors and 21 controls. There were no significant differences in the frequency of adverse outcomes (PE, foetal death, and infants with abnormal birth weight), sFlt-1, PlGF, the sFlt-1/PlGF ratio, or birth weight centiles between the PE-risk and control groups. The most frequently recorded high-risk factor was gestational diabetes mellitus, whereas moderate risk was a pre-pregnancy body mass index of over 30 kg m –2 . The most prominent difference was observed in the subgroups with gestational hypertension and first-time pregnant women as risk factors, with significantly higher sFlt-1/PlGF ratios compared to the control group. Combining multiple risk factors increased the sFlt-1/PlGF ratio compared to both the control group and the group with only one risk factor. The study documented PE risk factors and outcomes at a Croatian hospital where angiogenic markers are not routinely used in screening. Findings highlighted the importance of integrating PE screening into standard practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaVascular Endothelial Growth Factor Receptor-1Placenta Growth FactorAngiogenesisHumansFemalePregnancyRisk FactorsAdultPregnancy OutcomeDiabetes, GestationalBiomarkersBody Mass IndexBirth WeightCase-Control Studies

Stichwörter der Autor:innen

preeclampsiarisk factorsscreening

Substanzen

Vascular Endothelial Growth Factor Receptor-1Placenta Growth FactorFLT1 protein, humanPGF protein, humanBiomarkers

Autor:innen und Institutionen

  • Sestre Milosrdnice University Hospital Center, Department of Clinical Chemistry, 10000 Zagreb Croatia.
  • Sestre Milosrdnice University Hospital Center, Clinic of Gynaecology and Obstetrics 10000 Zagreb, Croatia.
  • Bethesda Hospital, Clinic for Gynaecology, 4052 Basel, Switzerland.
  • University of Zagreb Faculty of Pharmacy and Biochemistry, Department of Medical Biochemistry and Haematology, 10000 Zagreb Croatia.

ORCID-Profile: Adriana Bokulić, Dražan Butorac, Ivka Djaković, Marijo Čukelj, Marija Grdić Rajković

Zitieren

APA

Bokulić, A., Butorac, D., Djaković, I., Čukelj, M., & Rajković, M. G. (2025). Investigating preeclampsia risk factors and angiogenic profiles in low-screening area. Acta Pharmaceutica. https://doi.org/10.2478/acph-2025-0040

Vancouver

Bokulić A, Butorac D, Djaković I, Čukelj M, Rajković MG. Investigating preeclampsia risk factors and angiogenic profiles in low-screening area. Acta Pharmaceutica. 2025. doi:10.2478/acph-2025-0040

BibTeX
@article{Bokuli2025,
  author = {Bokulić, Adriana and Butorac, Dražan and Djaković, Ivka and Čukelj, Marijo and Rajković, Marija Grdić},
  title = {Investigating preeclampsia risk factors and angiogenic profiles in low-screening area},
  journal = {Acta Pharmaceutica},
  year = {2025},
  doi = {10.2478/acph-2025-0040}
}
Kostenlos starten →